ESPR: Esperion Therapeutics, Inc. Stock

by  •  • Comments Off on ESPR: Esperion Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 448.88
Enterprise Value ($M) 903.01
Book Value ($M) -454.99
Book Value / Share -2.40
Price / Book -0.99
NCAV ($M) -459.73
NCAV / Share -2.43
Price / NCAV -0.98

Profitability (mra)
Return on Invested Capital (ROIC) -1.01
Return on Assets (ROA) -0.34
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.87
Current Ratio 1.29

Balance Sheet (mrq) ($M)
Current Assets 201.06
Assets 205.80
Liabilities 660.79
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 116.33
Operating Income -155.56
Net Income -209.25
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -135.49
Cash from Investing 42.50
Cash from Financing 50.46

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A CVI Investments, Inc. 0.00 -100.00
02-14 13G/A Point72 Asset Management, L.P. 0.20 -95.37
02-14 13G/A Deep Track Capital, LP 0.00 -100.00
02-14 13G/A Two Seas Capital LP 6.80 -2.98
02-13 13G/A Vanguard Group Inc 4.52 20.59
02-09 13G/A Wasatch Advisors Inc
01-24 13G/A Bb Biotech Ag 3.70 0.00
01-17 13G/A Millennium Management Llc 3.20 -32.10
01-03 13G/A Meditor Group Ltd
06-08 13G/A BlackRock Inc. 4.90 -15.68

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-08 4,414,986 12,768,915 34.58
2024-05-07 9,208,366 34,283,905 26.86
2024-05-06 1,540,096 1,512,184 101.85
2024-05-03 1,509,337 5,530,903 27.29

(click for more detail)

Similar Companies
ELTX – Elicio Therapeutics, Inc. ELYM – Eliem Therapeutics, Inc.
EOLS – Evolus, Inc. ETNB – 89bio, Inc.
ETON – Eton Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io